Skip to Main Content

Author Details

William E Grizzle
University of Alabama at Birmingham
1974
517
83
PMIDPaper TitleJournal TitlePublished Year
36735117A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.Breast Cancer Res Treat2023
37509355Intraoperative Imaging in Hepatopancreatobiliary Surgery.Cancers (Basel)2023
37190208Immune Profile of Exosomes in African American Breast Cancer Patients Is Mediated by Kaiso/THBS1/CD47 Signaling.Cancers (Basel)2023
37341656Metrics for the Evaluation of Bioresources: Tell Us the Whole Story.Biopreserv Biobank2023
37233208Simultaneous Detection of Multiple Tumor-targeted Gold Nanoparticles in HER2-Positive Breast Tumors Using Optoacoustic Imaging.Radiol Imaging Cancer2023
36916704Immunophenotypic profiles and prognosis for colorectal mucinous adenocarcinomas are dependent on anatomic location.Cancer Med2023
36765604Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats.Cancers (Basel)2023
34979848Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent.Biotech Histochem2022
35801971The Use of Human Tissues for Research: What Investigators Need to Know.Altern Lab Anim2022
35631554Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery.Pharmaceutics2022
32744455The neutral red assay can be used to evaluate cell viability during autophagy or in an acidic microenvironment in vitro.Biotech Histochem2021
33557374Molecular Imaging of Inflammatory Disease.Biomedicines2021
33803201Diabetes, Obesity, and Inflammation: Impact on Clinical and Radiographic Features of Breast Cancer.Int J Mol Sci2021
34653338Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer.ACS Appl Mater Interfaces2021
31442303Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristics.Int J Cancer2020
32070401TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.Breast Cancer Res2020
31911279Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer.Transl Oncol2020
32823919Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo.Cancers (Basel)2020
32414099Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.Cancers (Basel)2020
32231273Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.Oncogene2020
30508389Commentary on Improving Biospecimen Utilization by Classic Biobanks: Identifying Past and Minimizing Future Mistakes.Biopreserv Biobank2019
31735720Issues in the Use of Human Tissues to Support Precision Medicine.J Health Care Poor Underserved2019
31502259Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research.Cancer2019
31568648Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy.Cancer Med2019
31188631Biospecimen Utilization: A Critical Challenge in Global Bioresource/Biobanking Operations.Biopreserv Biobank2019
31188628Biobank: What's in a Name?Biopreserv Biobank2019
31188629Biological, Medical, and Other Tissue Variables Affecting Biospecimen Utilization.Biopreserv Biobank2019
31188627The Utilization of Biospecimens: Impact of the Choice of Biobanking Model.Biopreserv Biobank2019
31188626The Importance of Human Tissue Bioresources in Advancing Biomedical Research.Biopreserv Biobank2019
29620220Translational control of the undifferentiated phenotype in ER⿿positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition.Oncol Rep2018
29912871AR negative triple negative or "quadruple negative" breast cancers in African American women have an enriched basal and immune signature.PLoS One2018
30121007A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.Neoplasia2018
30118979Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle.Biomaterials2018
30113239Factors that drive the increasing use of FFPE tissue in basic and translational cancer research.Biotech Histochem2018
30457879Lessons Learned During Three Decades of Operations of Two Prospective Bioresources.Biopreserv Biobank2018
30363516Nitrocellulose tissue prints: an innovative approach to preparing high quality DNA and RNA from prostate biopsies without compromising the cores for pathology diagnosis.Transl Androl Urol2018
29751044Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c.Cancer Lett2018
29686416Reply to "Phase II prospective randomized trial of weight loss prior to radical prostatectomy".Prostate Cancer Prostatic Dis2018
29377712Standard PREanalytical Code Version 3.0.Biopreserv Biobank2018
28030809Genomic regulation of invasion by STAT3 in triple negative breast cancer.Oncotarget2017
28114897Erratum to: Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer.BMC Cancer2017
29050202Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling.Oncotarget2017
28881355Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancer.Br J Cancer2017
28798901Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.Front Oncol2017
28762545Epigenetic risk score improves prostate cancer risk assessment.Prostate2017
27908970Noninvasive Imaging of Colitis Using Multispectral Optoacoustic Tomography.J Nucl Med2017
26200837The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?Appl Immunohistochem Mol Morphol2016
28164176BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.Int J Chronic Dis Ther2016
28626793Acidic pH-targeted chitosan capped mesoporous silica coated gold nanorods facilitate detection of pancreatic tumors via multispectral optoacoustic tomography.ACS Biomater Sci Eng2016
26658453Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.Lab Invest2016
  • 1 - 50 of 517

Recommended Authors

Center for Cancer Research, National Cancer Institute
Career Start Year 2008
Number of shared co-authors 2
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2002
Number of shared co-authors 0
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 1
Medical University of Innsbruck
Career Start Year 1999
Number of shared co-authors 0
Western University
Career Start Year 1999
Number of shared co-authors 0
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 2
The Francis Crick Institute
Career Start Year 1994
Number of shared co-authors 3
Georgetown University
Career Start Year 1993
Number of shared co-authors 0
Radboud University Medical Center
Career Start Year 1993
Number of shared co-authors 0
University of California Riverside
Career Start Year 1992
Number of shared co-authors 0
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 13
Washington University School of Medicine
Career Start Year 1987
Number of shared co-authors 2
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Career Start Year 1986
Number of shared co-authors 0
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 0
University of Utah
Career Start Year 1986
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute
Career Start Year 1985
Number of shared co-authors 1
Duke School of Medicine
Career Start Year 1984
Number of shared co-authors 1
Weill Medical College of Cornell University
Career Start Year 1984
Number of shared co-authors 5
Spanish National Cancer Research Centre-CNIO
Career Start Year 1983
Number of shared co-authors 4
University of Pittsburgh School of Medicine
Career Start Year 1982
Number of shared co-authors 3
Queen's University
Career Start Year 1982
Number of shared co-authors 4
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 2
The Norwegian Radium Hospital, Oslo University Hospital
Career Start Year 1980
Number of shared co-authors 0
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 8
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 1
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Career Start Year 1979
Number of shared co-authors 0
The Institute of Cancer Research
Career Start Year 1978
Number of shared co-authors 1
National Cancer Institute, National Institutes of Health
Career Start Year 1977
Number of shared co-authors 4
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 2
Oregon Health and Science University
Career Start Year 1973
Number of shared co-authors 6

Collaborators

National Cancer Institute
Co-authored papers 22
University of Alabama at Birmingham
Co-authored papers 18
University of Zambia
Co-authored papers 12
University of Alabama at Birmingham and Birmingham VA Medical Center.
Co-authored papers 11
George Washington University School of Medicine and Health Sciences
Co-authored papers 8
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Co-authored papers 8
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham
Co-authored papers 8
University of Texas MD Anderson Cancer Center
Co-authored papers 7
The University of Kansas Medical Center
Co-authored papers 7
Eastern Virginia Medical School
Co-authored papers 7
University of Michigan Medical School
Co-authored papers 6
HudsonAlpha Institute for Biotechnology
Co-authored papers 6
University Medical Center Utrecht
Co-authored papers 5
CHRISTUS Santa Rosa Hospital-Medical Center
Co-authored papers 5
Huntsman Cancer Institute
Co-authored papers 5
Cincinnati Children's Hospital Medical Center
Co-authored papers 5
University of Alabama at Birmingham
Co-authored papers 5
Queensland University of Technology
Co-authored papers 5
Co-authored papers 5
Heersink School of Medicine, The University of Alabama at Birmingham
Co-authored papers 4
Co-authored papers 4
Division of Clinical Chemistry, Johns Hopkins University
Co-authored papers 4
Co-authored papers 4
Mayo Clinic
Co-authored papers 4
University of Alabama at Birmingham
Co-authored papers 3
University of Alabama at Birmingham
Co-authored papers 3
Eastern Virginia Medical School
Co-authored papers 3
University of Pittsburgh Medical Center
Co-authored papers 3
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 3
Huntsman Cancer Institute, University of Utah
Co-authored papers 3